Latest News
An important subsidiary of the company emerged from Chapter 11 bankruptcy.
Via The Motley Fool · October 2, 2026
Zymeworks (NASDAQ:ZYME) said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a commercial organization to its business.
Management said the transaction represent
Via MarketBeat · October 2, 2026
If you like monthly income, this mix of five real estate, industrials, and energy stocks can pay you attractive monthly dividends.
Via The Motley Fool · October 2, 2026
The Magnificent Seven stock is trading 12% below its all-time record.
Via The Motley Fool · October 2, 2026
It completed a critical phase in one of its advanced data center complexes.
Via The Motley Fool · October 2, 2026
Both Lucid and Stellantis have been significantly sold off, but if their turnarounds make a financial impact in the near term, investors could be positioned for big returns over the next five years.
Via The Motley Fool · October 2, 2026
The share price is right where it was in May. Is the stock cheaper today?
Via The Motley Fool · October 2, 2026
CareTrust REIT (NYSE:CTRE) announced a strategic partnership with U.K. care-home developer and operator LNT, combining the company’s newer growth initiatives in U.K. care homes and senior housing operating partnerships, or SHOP, in a transaction valued at approximately $1.4 billion.
The transaction
Via MarketBeat · October 2, 2026
Experts predict a "transformative trajectory" for copper demand.
Via The Motley Fool · October 2, 2026
The memory maker's shares gained after a record quarter and a bigger spending plan. What does its post-report record say now?
Via The Motley Fool · October 2, 2026
You wouldn't expect that from a company that posted an estimates-beating quarter.
Via The Motley Fool · October 2, 2026
Tesla's Q3 deliveries of 486,532 vehicles topped consensus estimates by roughly 25,000 units, signaling sustained demand momentum, today, Oct. 2, 2026.
Via The Motley Fool · October 2, 2026
Is Tilray's situation hopeless?
Via The Motley Fool · October 2, 2026
Rivian's record Q3 delivery beat lifted shares early before investors refocused on unchanged guidance and the Oct. 29 earnings call, today, Oct. 2, 2026.
Via The Motley Fool · October 2, 2026
Ur Energy (NYSEAMERICAN:URG) President and CEO Matt Gili outlined the uranium producer’s expansion plans in Wyoming, emphasizing the company’s in-situ recovery, or ISR, operations at Lost Creek and Shirley Basin and its longer-term goal of building a larger regional production platform.
Gili descri
Via MarketBeat · October 2, 2026
These two undervalued TSX stocks have both suffered steep declines, but their fundamentals suggest the underlying businesses still have plenty going for them.
Via The Motley Fool · October 2, 2026
This monthly dividend stock offers an attractive mix of nearly 5% yield, monthly distributions, and a deeply discounted unit price with a large Canadian rental portfolio.
Via The Motley Fool · October 2, 2026
Recovering and reusing one half of one fairing saved SpaceX the cost of building two entire Falcon 9 rockets over the last eight years.
Via The Motley Fool · October 2, 2026
Trade tensions can raise specific retail costs even when overall grocery inflation is slowing, putting purchasing scale at a premium.
Via The Motley Fool · October 2, 2026
Occidental Petroleum, ExxonMobil, and Energy Transfer are still reliable income plays.
Via The Motley Fool · October 2, 2026
The new company has a new name, but the same problems.
Via The Motley Fool · October 2, 2026
These two TSX stocks offer ways to prepare for the next market pullback, with fast growth and steady profitability.
Via The Motley Fool · October 2, 2026
MaxLinear stock gained more than 50% last month. Here is what powered the surge and what could trip it up.
Via The Motley Fool · October 2, 2026
Dutch Bros stock has plummeted 40% in the past two months.
Via The Motley Fool · October 2, 2026
The company's search for its next wave of billion-dollar drugs continues.
Via The Motley Fool · October 2, 2026